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Abstract 
 
Despite significant efforts to curtail the impact of the opioid epidemic, overdose deaths 
continue to grow exponentially across the United States (Ahrnsbrak et al., 2017).. With 22 of the 
top 25 cities for opioid abuse in the Southeastern United States, including 4 in North Carolina 
alone, it is crucial to consider new and innovative interventions in the political context of the 
South to effectively combat the negative effects of this crisis (Knopf, 2017). Safe injection 
facilities are a harm reduction method that have been proven to decrease the likelihood of drug 
overdose and connect injection drug users to reliable healthcare information in other countries, 
but they have yet to launch in the United States due to social and legal obstacles (Small et al., 
2008). Using in-depth interviews with public health officials, medical providers, and law 
enforcement officers across North Carolina, I explored the potential benefits and concerns that 
key stakeholders have concerning the potential implementation of safe injection facilities in 
response to the opioid crisis. Interviews were audio-recorded with consent, transcribed, and 
coded by hand for thematic analysis to identify prevailing claims, concerns, and challenges 
associated with the implementation of SIFs in North Carolina. By using the themes and related 
information collected in this study, public health workers, legislators, and policy advocates can 
make informed decisions about how to effectively and efficiently pass policy that benefits the 
overall health and safety of injection drug users and the general population in North Carolina. 
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 4 
Introduction  
 
Despite significant efforts to curtail the impact of the opioid epidemic, overdose deaths in 
the United States continue to grow at rates far above those in other countries (Lopez, 2017). With 
approximately 52,000 drug overdose deaths in 2015, the opioid epidemic remains a major public 
health crisis (Lopez, 2017). Historically, many interventions, such as prescription monitoring and 
pharmacy lock-in programs, have focused on addiction prevention. Alternatively, harm-reduction 
methods, defined as interventions that reduce the negative consequences of a problem rather than 
prevention, can help prevent accidental overdose in the population of those that are addicted. In 
particular, safe injection facilities (SIFs) are a harm reduction approach that aims to decrease 
opioid overdose by providing a medically supervised environment where drug users can 
consume illicit drugs intravenously (Small et al., 2008). SIFs help decrease the likelihood of drug 
overdose by providing sterile injection equipment, reliable drug and healthcare information, and 
quick access to medical staff in the case of an emergency (Hedrich, 2004).  
 The threat of political backlash hinders the implementation of SIFs in the United States. 
Critics of SIFs often prefer to direct taxpayer dollars towards interventions focused on addiction 
prevention and treatment, and claim that SIFs would exacerbate the overall issue by enabling 
drug abuse and normalizing illicit substances (Elliot, Malkin, Gold, 2002). This argument has 
prevented the adoption of SIFs in the United States, despite significant evidence of their efficacy 
and effectiveness in other countries. Due to the politically volatile climate surrounding this topic, 
it is important for policymakers to consider all of the involved stakeholders before implementing 
such an intervention.  
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 Few stakeholder analyses of safe injection facilities have been published, and fewer are 
focused on the political environment in the Southeastern United States, which has 22 of the top 
25 cities in America for opioid abuse. Moreover, North Carolina has four cities from this list, 
including the number one city (Knopf, 2017). Thus, implementing SIFs across the Southeast 
could vastly decrease the rate of overdose deaths caused by opioid abuse.  Due to the lack of 
agreement in which strategies to implement, it is important to critically examine the stakeholders 
that would be involved in this specific region to determine the feasibility and efficacy of 
implementing such an intervention. This stakeholder analysis is crucial to determine if potential 
positive effects can outweigh opposing political repercussions. 
Research Question 
By analyzing qualitative data from interviews with medical providers, law enforcement 
officials, public health advocates, and health policy experts, I will address the following 
questions: 
Ø What claims and concerns do various stakeholders express about the use of SIFs as a 
harm reduction method? 
Ø What are the challenges that limit the feasibility of implementing SIFs for the use of 
opioid users in the state of North Carolina?  
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Background 
 
The opioid epidemic is one of the largest public health problems ever experienced in the 
United States. Over the past 2 decades, this epidemic has grown at unprecedented rates, with the 
consumption of hydrocodone increasing by more than 200% and 500%, respectively, between 
1999 and 2011 (Kolodny et al., 2015). The Substance Abuse and Mental Health Services 
Administration estimated that almost 12 million Americans misused opioids in 2016, with almost 
1 million of those being heroin users (Ahrnsbrak et al., 2017). Furthermore, the rate of overdose 
death related to opioid pain relievers quadrupled during this time frame, which coincided with a 
900% increase in people seeking treatment for addiction to opioid pain relievers between 1997 
and 2011 (Kolodny et al., 2015). These striking increases in opioid consumption and related 
deaths has led to what the Center for Disease Control (CDC) has labeled the “worst drug 
overdose epidemic in [US] history” (Paulozzi 2010, p. 47). 
Additionally, the total economic burden of the opioid crisis is estimated to be $78.5 
billion, with costs directly linked to fatalities from opioid overdose estimated at $21.5 billion 
(Florence et al., 2016).  This economic burden is mostly borne by the government on local, state, 
and federal levels, with an estimated 25% of the economic burden being funded by public 
sources (Florence et al., 2016). As a result, society is paying dearly for the opioid epidemic, 
through increased health care costs and insurance premiums, forgone productivity and tax 
revenue, and social programs aimed at treating substance abuse. 
In North Carolina, the opioid epidemic has been particularly destructive. North Carolina 
is home to four of the top 25 cities for opioid abuse in America as determined by the percentage 
of prescription holders who abuse, including Wilmington and Hickory, which are ranked number 
1 and 5, respectively (Knopf, 2017). Throughout the state, there are approximately 3 opioid 
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overdose deaths, 9 related hospitalizations, 12 related emergency room visits, 1,140 instances of 
opioid misuse, and 25,500 opioid prescriptions dispensed every day (NC State Center for Health 
Statistics, 2016). The number of unintentional opioid deaths in North Carolina has increased 10-
fold since 1999, with heroin and other synthetic narcotics being involved in over half of these 
cases in 2016 (NC State Center for Health Statistics, 2016). As the opioid crisis continues to 
facilitate greater utilization of injection drug use, the public safety of North Carolina’s citizens is 
jeopardized by the increased crime (Small et. al., 2007), violence (Haynes, 2015), hepatitis and 
HIV cases (Metz, Sullivan, Jones, 2018), loss of productivity (Birnbaum et. al., 2011) and 
incapacitated driving (Searle, 2017) that are associated with these behaviors. The consequences 
of this crisis create a major financial burden, with the CDC estimating the total cost of the opioid 
crisis to North Carolina at over $1.3 billion in 2015 alone (CDC WISQARS, 2010). Ultimately, 
the opioid epidemic results in three major consequences for North Carolina and its citizens: 
increased morbidity and mortality connected to prescription opioids and related drug use, 
negative externalities and societal risks that harm public safety, and an overwhelming economic 
burden that is largely borne by public funds. 
While most public health professionals agree on the severity of the opioid epidemic, there 
is much debate about how to best respond to this crisis. This debate can be broken into three 
Addiction 
Prevention
•Targets those at risk for opioid addiction
•Decreases surplus of prescription opioids
•Reduces superfluous prescribing practices
Treatment
•Targets those who regularly use and abuse opioids
•Increases access to both physical and mental healthcare services
•Provides evidence-based treatment for addiction
Harm 
Reduction
•Targets those who regularly use and abuse opioids by prioritizing pubilc safety
•Eliminates negative consequences of drug use
•Connects users to medical resources and fights for basic human rights
Figure 1: Approaches to Solving the Consequences of the Opioid Crisis 
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categories of solutions: addiction prevention, treatment, and harm reduction (Hawk, Vaca, 
D’Onofrio, 2015). Each of these solutions aims to tackle a different aspect of the crisis and 
alleviate the consequences of increased morbidity and mortality, decreased public safety, and 
increased financial burden as summarized in Figure 1.  More specifically, harm reduction 
methods center around individuals who are already addicted, with a focus on eliminating the 
consequences of the opioid crisis and increasing the quality of life for addicts (Marlatt et al., 
2011). These methods are primarily controversial because do not directly prevent addiction from 
occurring, nor directly provide treatment, and they involve extensive policy changes that involve 
exceptions in criminal law for addicts. 
One harm reduction method that has been creating extensive dialogue in public health 
spheres for over two decades are safe injection facilities (SIFs). SIFs are medically supervised 
facilities that provide a secure, hygienic place for injection drug users (IDUs) to self-administer 
previously obtained illicit drugs with healthcare providers on hand to intervene in the event of 
any complications or overdose (Small et al., 2008). Additionally, SIFs serve as a link to 
healthcare and health education for IDUs who are more likely to lack important preventative 
healthcare resources due to barriers from cost, transportation, stigma, and discrimination (Small 
et al., 2008). These facilities are currently found in a handful of large cities throughout Europe, 
Canada, and Australia, with no legally sanctioned SIF currently operating in the United States. 
Since many IDUs lack sterile injection equipment or an innocuous place for injecting, 
SIFs are essential to providing a secluded environment for IDUs to avoid public injection and 
administer drugs outside of public parks or department store restrooms, and to receive helpful, 
reliable healthcare information. Additionally, SIFs are even more important when considering 
the stigma IDUs face from law enforcement, resulting in an increased anxiety that deters IDUs 
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from following safe, hygienic injection practices (Small et al., 2006). This fear of the criminal 
justice system discourages IDUs from utilizing needle exchange programs, resulting in increased 
syringe sharing and improper syringe disposal (Small et al., 2006). All of these factors increase 
the risk of infectious disease transmission and fatal overdose, despite the wide availability of 
needle exchange programs and initiatives to distribute naloxone for reversing the onset of 
overdose. This environment of fear among IDUs increases the risks from public injection, which 
acts as a significant barrier to maintaining public safety and controlling crime (Small et al., 
2007). Thus, local officials must consider small-scale harm reduction interventions, such as SIFs, 
that do not compromise the health and safety of IDUs and the general public. 
As a harm reduction method, SIFs have been shown to reduce the negative consequences 
of injection drug use associated with the opioid crisis, including reductions in needle/syringe 
sharing (Kerr et. al., 2005 & Stolz, Wood, Small, 2007) public injecting and publicly discarded 
syringes (Wood, Kerr, Small, 2004, Thein et. al., 2005, & Kerr et.al., 2007) overdoses (Hedrich, 
2004) and increased enrollment in drug treatment (Wood, Tyndall, Zhang, 2006) without 
increases in relapse rates (Kerr, Stolz, Tyndall, 2006) or drug related crime (Wood et. al. 2006). 
IDUs have an increased risk of fatal overdose and transmission of blood borne infections, and 
this is only exacerbated by the social and legal factors that work against IDUs (Fairbairn et al., 
2008). Through SIFs, IDUs have increased access to healthcare resources, including addiction 
treatment, which has been shown to decrease their risky health behaviors and improve their 
health outcomes (Small et al., 2008). Despite this evidence, SIFs are fiercely debated due to their 
facilitation of illicit substance use by IDUs.  
As with any controversial issue, it is necessary to consider all involved parties using a 
stakeholder analysis. This technique developed out of business management practices as a 
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method of attending to “any group or individual who can affect or is affected by the achievement 
of an organization’s objectives” (Bryson 2004, p. 46). This tool is used to answer questions about 
the position, influence, and invested interests of stakeholders on a particular issue, and to 
understand the decision-making process that stakeholders utilize in a specific context (Brugha 
and Varvasovszky, 2000). This is particularly important for public health organizations, and can 
be critical in launching an intervention by distinguishing potential allies from prospective threats. 
Stakeholder analysis has been a fundamental part of implementing many controversial public 
health interventions in the past, including needle exchange programs for IDUs (Philbin and 
FuJie, 2014), wide-spread availability of contraceptives (Petruney et al., 2010), and mandatory 
vaccine programs (Nodulman et al., 2015). 
In the case of SIFs, stakeholders are defined as any person, group, or organization that is 
affected by or has influence over the implementation and operation of an intended SIF. This 
includes government officials, pharmacists, health care providers, IDUs, local public health 
organizations, drug treatment providers, law enforcement personnel, and community leaders. By 
conducting qualitative interviews with these stakeholders, we can map the dialogue surrounding 
SIFs in North Carolina and explore the feasibility and acceptance of this intervention as a 
method of reducing opioid-related harm. Due to the scale of the opioid epidemic and its 
consequences, we must consider controversial harm reduction interventions such as SIFs as a 
possibility to reduce the overall harm and cost to society. By conducting a stakeholder analysis, 
we will examine the position, influence, and interests of all involved parties and begin to 
understand the potential benefit of SIFs and how these compare to their disadvantages. From this 
understanding, public health leaders can make decisions about the political possibility of SIFs 
and how to further proceed with developing their structure, position, and promotion.  
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Methods  
 
Research Design and Data Source 
 Using in-depth qualitative interviews conducted from February 2018 - March 2018, with 
8 key stakeholders -- legal professionals, public health officials, law enforcement personnel, and 
medical providers -- I explored the current dialogue and acceptability of safe injection facilities 
for the purpose of reducing drug-related harm in North Carolina. These groups were identified as 
stakeholders based on their influence and interaction with drug related policy and injection drug 
users. To ensure a diverse array of perspectives and understanding of acceptability of safe 
injection facilities in this region, I used a targeted sampling method adapted from the Rapid 
Policy Assessment and Response (RPAR) techniques for interviewing two levels of stakeholders, 
experts and interactors, across three concentrations -- public health, policy, and treatment. RPAR 
techniques were first developed as a legal analysis that uses empirical data to evaluate how 
structural factors can impact local-level public health interventions (Burris & Lazzarini, 2006). 
Participants and Sampling Methods 
Upon identification of an initial list of experts and informants, each interviewee was 
approached with an explanation of the study. After obtaining informed consent, each individual 
was then asked background questions to assess key demographics, such as education level, age, 
and gender. The interviews themselves were semi-structured, with a focus on general opinions 
and awareness of IDUs and the opioid crisis, barriers and limitations to safe injection facilities 
and other harm reduction methods, and implementation recommendations (Appendix A). 
Interventions-specific questions were prefaced with definitions and explanations in an effort to 
standardize the minimum level of understanding for each participant. In each interview, potential 
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candidates for future interviews were solicited and snowball sampling was used to further 
explore critical stakeholders and experts. These interviews were conducted telephonically to 
maximize convenience, accessibility, safety, and comfort for the participants.  
Data Analysis Methods 
Interviews were approximately 30 minutes long, and digitally recorded. These recordings 
were destroyed after being transcribed and coded to ensure anonymity. To reflect the new 
information found during the study, content analysis was conducted simultaneously with 
interviewing and interview guides were adjusted accordingly. A thematic analysis was conducted 
in an adapted style of that created by Guba and Lincoln (1989), categorizing themes into claims, 
concerns, and challenges that stakeholders express. Claims identified assertions that stakeholders 
held about favorable aspects of the program, concerns characterized assertions regarding 
unfavorable aspects of the program, and challenges represented potential occlusions to reconcile 
before successful implementation of the program (Guba and Lincoln, 1989). The data identified 
general themes concerning harm reduction in North Carolina, the acceptability of safe injection 
facilities, barriers and limitations foreseen by stakeholders, and implementation suggestions. The 
transcripts of the interviews were hand-coded, and a codebook was created with key themes and 
concepts. These concepts were used to identify the general claims, concerns, and perceived 
challenges of each stakeholder in relation to safe injection sites.  
Limitations 
As with other stakeholder analyses and snowball sampling studies, this study has the 
strength of adaptation, and aims to characterize the dynamic environment around self-injection 
sites. As a result, a limitation of this study is that many interviewees have limited knowledge 
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about safe injection facilities, or harm reduction and the opioid crisis in general, which made it 
difficult for them to form fully informed and thoughtful opinions about the issue. Since a brief 
description was provided in the interview, these results may more effectively characterize the 
initial reactions to stakeholders rather than their fully formed opinions. Additionally, this study 
was limited by the number of stakeholders that could be interviewed with the resources at hand, 
as well as by which stakeholders were willing to speak about such a politically contentious issue, 
and therefore may not be fully representative of the population in North Carolina. 
Ethical Considerations 
Since this study is concerned with the use of illicit substances and injection drug users, 
there are ethical concerns with maintaining anonymity and privacy of individuals who consent to 
being interviewed. Every measure was taken to protect the privacy of individuals and de-identify 
their responses so they would be free of any emotional, legal, or social repercussions. The 
Institutional Review Board at the University of North Carolina at Chapel Hill reviewed and 
exempted this study. 
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Results 
 
 The eight stakeholders interviewed consisted of 4 expert level and 4 interactor level 
participants. As described in Figure 2, their professions included public health advocacy and 
operations (n=3) and health policy law (n=1) as expert level stakeholders, as well as local law 
enforcement (n=2) and emergency medical services (EMS) (n=2) composing the interactor level 
stakeholders. Despite the different professions of the participants, they were all familiar with the 
basic consequences of the opioid crisis in relation to North Carolina, with some varying degrees 
of knowledge into specific local consequences and comparisons on a national level. They all 
expressed awareness of harm reduction methods and many of the participants have spent 
significant time in their professional careers interacting with the North Carolina Harm Reduction 
Coalition. In relation to perceived benefits and concerns surrounding safe injection facilities, 
attitudes were assessed for each stakeholder group in regards to three main areas: claims, 
concerns, and challenges. In regards to 
these themes, claims represent the 
perceived benefits and factors that support 
the implementation of SIFs, concerns 
characterize the worries that these 
stakeholders hold, and challenges signify 
the hurdles that are currently obstructing a 
clear path towards the possible 
implementation of SIFs within North 
Carolina. 
 
Expert 
Level
Public Health 
Advocacy and 
Operations
Health Policy 
Law
Interactor 
Level
Local Law 
Enforcement
Emergency 
Medical 
Services
Figure 2: Stakeholder Groups 
 15 
Claims 
SIFs are Effective at Promoting Health and Safety for IDUs 
All of the public health experts interviewed demonstrated extensive knowledge and 
personal experience with SIFs, and were adamant that SIFs achieve their designed goals of 
improving public safety and reducing morbidity and mortality amongst injection drug users. 
They referenced peer reviewed research that informed these claims, and demonstrated familiarity 
with the positive effects that SIFs have had in communities outside of the United States. 
“We know that the highest risk of overdose is when you’re actually consuming the drug, 
so if you can be in a place where if you do overdose, it’s not gonna lead to overdose 
death—that’s a good thing. That’s what they are designed to do, that’s what they do—the 
evidence is overwhelming.” 
–Health Policy Lawyer 
 
“I think if it was purely based off of scientific merits, then there wouldn’t even be a 
conversation about this.” 
–Public Health Advocacy Organization Staff Member 
 
These opinions were echoed in the interviews with law enforcement officials, as well as 
EMS providers. While both groups demonstrated less knowledge on the secondary benefits of 
SIFs, many indicated confidence in their effectiveness for decreasing mortality, with one EMS 
provider stating “no one has ever died at a safe injection or safe consumption center.” They also 
expressed understanding in the consistency with harm reduction philosophy and other harm 
reduction methods, despite the presence of personal comfort with the intervention. 
“I understand the science behind safe injection sites and how that can be a good thing, but 
like I still am like, “I don’t know man, it’s kind of weird.” I think you’d get that gamut of 
opinions across law enforcement.” 
–Law Enforcement Officer 
 
SIFs are Effective at Improving Public Safety 
Law enforcement officers focused on potential benefits of SIFs for public safety, 
primarily including the effects of decreasing public intoxication and publically discarded 
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syringes. These opinions were influenced by personal anecdotes on the job that primarily 
involved the harm or increased harm of innocent bystanders as a result of IDU behavior. 
“People who are using are gonna try to find places to use and often times leave behind 
byproducts of that use. So, the potential there for a child to come in contact with that 
needle or anyone else for that matter is one of concern. So immediately when you talk 
about safe injection facilities, I think about maybe that reduces the number of encounters 
at a McDonald’s bathroom.” 
–Law Enforcement Officer 
 
While EMS providers did not express as much familiarity with public safety benefits of 
SIFs, the theme of effectiveness towards improving public safety was reflected in the responses 
of many of the public health experts. These perceived benefits were influenced by peer reviewed 
research on both underground SIFs in the United States and legally operating SIFs abroad, 
resulting in “decreased public nuisance and injection in the public domain,” “decreased HIV and 
hepatitis,” and “decreased crime in the public domain.” 
“Most importantly, it will decrease drunk driving and inebriated driving. So, in cities 
which are being hard hit by traffic fatalities and traffic injuries related around drug use, 
what a fabulous thing to do and help people not use while in motor vehicles, and not use 
in parking lots and drive off because you can medically check people.” 
–Public Health Advocacy Organization Staff Member 
 
Common Sense Policy 
Despite differing comfort with the possibility of SIF implementation, members from each 
of the four stakeholder groups expressed understanding of how SIFs fit into the overall harm 
reduction philosophy and spoke to how much it aligned with common sense. This idea of 
common sense policy was more comfortable for the public health advocates and the EMS 
providers who expressed more familiarity with harm reduction, but it was also present in the 
responses of law enforcement despite clear discomfort with the concept of medically supervised 
and legally-authorized injection drug use. 
“With safe injection facilities, the benefits are amazing—it’s just common sense.” 
 17 
–Public Health Advocacy Organization Staff Member 
 
“I think the safe injection idea is a logical pretty big step forward—but also a logical 
extension of those other philosophies…To me, the idea of administering narcan to 
someone is not that different from having medical supervision while someone uses, and 
those things are not philosophically very far apart in my head.” 
–Law Enforcement Officer 
 
SIFs Demonstrate Compassion and Humanity 
 Another common claim that several public health experts and EMS providers expressed 
is the idea that SIFs are an intervention that demonstrate humanity and compassion towards 
IDUs. This theme primarily focuses on SIFs as a way to show support to those that are in the 
throes of addiction, and to demonstrate concern for the lives of this vulnerable population. This 
epidemic has had a major effect in close-knit rural communities, where everyone has been 
directly impacted by the crisis, and SIFs are an intervention that can rebuild a ravished 
community by demonstrating compassionate care.  
“I think when you humanize healthcare, it can become incredibly fulfilling as a provider, 
but it also is incredible for the patient to feel like they’re cared for. And I think the nature 
of IV drug use, most of these folks are very disenfranchised, with their social support 
networks, and I think trying to reconnect them to that becomes really an essential part of 
their recovery.” 
–EMS Provider 
 
“Now in a lot of rural communities, which I think have had an undue burden of the opiate 
epidemic, the people who are dying are people who everybody know. So, I think there 
will be a shocking amount of support [for SIFs] in some of the rural areas and 
conservative jurisdictions because that’s where everybody grew up together and they’re 
sick of seeing their loved ones die.” 
–Public Health Advocacy Organization Staff Member 
 
“It’s just a hotbed of harm reduction down here [in North Carolina], and people are really 
engaged and they want to work, and they want to save lives…harm reduction is treating 
people with dignity and respect, that’s the golden rule—do unto others as you’d have 
others do unto you.” 
–Public Health Advocacy Organization Staff Member 
 
“The majority of people who are injecting drugs would prefer not to be, if there was a 
way that they could—and it’s a really, really hard transition and you need people you are 
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going to treat you like a human being, [which is a foundational belief of harm reduction 
and SIFs].” 
–Health Policy Lawyer 
 
Concerns 
SIFs Stifling Treatment 
 One of the primary concerns expressed in the interviews across stakeholder groups is the 
concern that SIFs would become a substitute to implementing treatment interventions which 
increase access to medication assisted treatment. While these stakeholders viewed SIFs as a 
necessary piece of the puzzle for solving the opioid crisis, they were not convinced that SIFs 
were the most impactful intervention. Ultimately, they believed that SIFs should be utilized as a 
part of a greater response to the opioid crisis that provides a comprehensive set of public health 
policy targeting prevention, treatment and harm reduction. 
“I think that supervised injection facilities are great, they should absolutely be part of the 
response. [But,] it doesn’t replace evidence-based treatment.” 
–Health Policy Lawyer 
 
“I believe that monitored injection sites are the next step in that continuum of harm 
reduction. I don’t know how heavily they would be utilized, but I do know that at a 
monitored site, the likelihood of a fatality from an overdose is exponentially lower. So, 
from the medical side it makes a lot of sense to me that it would be available in our 
continuum, and do that along with safe injection practices and other harm reduction 
strategies.” 
–Law Enforcement Officer 
 
“I think [the most effective way to promote health and safety among injection drug users 
in North Carolina is] a combination between safe consumption sites and targeted mobile 
outreach and syringe exchange. Because even if we do create safe consumption sites, not 
everyone is going to visit and not everyone is going to be able to visit.” 
–EMS Provider 
 
SIFs Stifling Prevention 
 Related to the concern of SIFs being perceived as a replacement for treatment, 
stakeholders also expressed concern for SIFs becoming implemented as a replacement for 
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addiction prevention. Since SIFs are inherently targeted at opioid abusers in the latest stages of 
addiction, there is a tendency to overlook interventions that can prevent users from reaching the 
stage of injecting. While SIFs are proven to help people in this stage, there is concern that this 
intervention could dilute the focus on prevention and mental health services that are necessary 
for combating the opioid crisis. 
“Sometimes I think we do people a disservice by jumping to people who are injecting 
drugs and all of the stereotypes that come with that. They kind of sort of [portray] people 
who are using drugs in a way that is harmful to themselves and to their families, but 
[separate themselves from IDUs by saying] ‘Wow, I never shot heroin, I’m not one of 
those people.” 
–Health Policy Lawyer 
 
“The lack of investment in mental health services in North Carolina is a primary driver of 
the opioid crisis [and should be a priority].”  
–Public Health Advocacy Organization Staff Member 
 
SIFs’ Relation to Other Drug Use 
 While SIFs have been widely debated in the public within the context of the opioid crisis, 
many stakeholders expressed concern for how this intervention would work for users of other 
intravenous drugs. The framework for existing SIFs abroad is not set up exclusively for opioid 
users, and many of the public health officials echoed the idea that successful implementation of 
SIFs must also include access for users of cocaine, methamphetamines, and other illegal drugs, 
especially since the opioid epidemic is so intertwined with the use of other drugs. In regards to 
associated stigma of these drugs, stakeholders also expressed concern that the general public 
regarded the use of all IV drugs as unacceptable. While it is reasonable that the general public 
may allow the implementation of SIFs as a response to the extenuating consequences from the 
opioid crisis, stakeholders expressed concern that many may not consider this intervention 
acceptable for non-opioid associated drugs.  
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“I am deeply concerned that they’ll do this [SIFs] for opiates only and if the opiates ever 
get under control then they’ll throw everybody else under the bus, especially meth users.” 
–Public Health Advocacy Organization Staff Member 
 
“I think that there’s large scale education that really needs to happen, like really 
regionally. There’s certainly a lot of conversation in the media, you know, like what does 
it mean to have safer injection facilities. That’s not just opioids, we’re talking about 
people who are into shooting crack, or methamphetamine, or [et cetera].” 
–Public Health Advocacy Organization Staff Member 
 
Privacy for IDUs 
One of the primary concerns expressed by both public health advocacy staff members 
and law enforcement is that of privacy for IDUs. Since SIFs typically operate on a bring your 
own policy, those who would use a SIF are likely participating in illegal activity with a dealer 
and individually in the form of possession of a controlled substance. The concern with this, is 
that people may be hesitant to use a SIF if they believe a law enforcement officer could monitor 
their activity at the site, proceed with surveillance, and ultimately arrest the user or their dealer 
off site from the SIF.  
“Clearly someone walking in the front door, as you said, it’s BYO. Which means 
someone has acquired these substances and almost undoubtedly acquired them illegally 
and therefore the possession is also illegal. So, on its face, that’s a legal hurdle that you 
just kind of have to reconcile.” 
–Law Enforcement Officer 
 
“My biggest concern, what I stated earlier is, my fear of law enforcement, like waiting 
outside, or waiting around the corner, or hiding somewhere watching these drug users 
come and go. Watching them, and then following them to the big-time drug dealers, just 
that would be my biggest fear over all, is continuing the secret or public criminalization 
of drug users in general.” 
–Public Health Advocacy Organization Staff Member 
 
Not in My Backyard (NIMBY) 
 Another common concern with the logistics of implementing SIFs that was mentioned by 
the public health experts is that of the “not in my backyard” contingent. This theme centers on 
the idea that people do not want to live next to a facility that caters to drug users and potentially 
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attracts crime, violence, and other negative externalities that are associated with drug use. While 
most of the stakeholders that were interviewed did not cite this as a personal concern, they did 
discuss this as a common concern for the general public. 
“Then you have the NIMBY [Not In My Backyard] people who are kind of like “well, 
you know I’m not saying I don’t understand what you’re saying but I don’t want a bunch 
of junkies in my backyard.” And that’s not, not understandable. You know, of course the 
counter to that is that people are already using drugs and overdosing in your backyard.” 
–Health Policy Lawyer 
 
As mentioned by some stakeholders, this can be combated with statistics and anecdotes 
about people using injection drugs regardless of the implementation of a safe injection facility; 
however, some people still expressed discomfort with the implementation of SIFs even with a 
close connection to addiction in their own neighborhood. 
 “I’ve kind of seen it firsthand, personally, and when it comes to safe injection sites, I 
mean I understand conceptually the science behind it, I understand the thinking behind it, 
I understand the harm reduction philosophy behind it. It still is a little bit far of a reach 
for me to be completely comfortable with it.” 
–Law Enforcement Officer 
 
SIFs are Perceived as Enabling Drug Use 
 One of the universal concerns that was expressed across stakeholder groups was the 
belief that SIFs (along with harm reduction interventions in general) enable IDUs to use and 
promote illegal and unhealthy behavior. This has been a concern in every educational campaign 
related to harm reduction, from syringe exchange to naloxone distribution, and continues to be a 
struggle with SIFs. While there are ways to educate people on the effectiveness of SIFs as an 
intervention, this preconceived notion of SIFs enabling dangerous and illegal activity is a major 
concern if they are going to be successfully implemented in North Carolina. 
“I think the other thing we continue to fight is the whole stigma of, we’re enabling drug 
use. When I started first doing naloxone distribution, that was the most common thing 
that we heard [but] the reality is that they were already using the drugs” 
–EMS Provider 
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“People think we’re just enabling people to shoot more drugs. I presume that’s the 
number one thing. It’s the same reason that people fought us on naloxone, and people 
fought us on syringe exchange for a while.” 
–Public Health Advocacy Organization Staff Member 
 
“I think there are certain moral parts of our country that struggle with the idea that you in 
some ways enable the behaviors [of injection drug use] … and fundamentally that would 
be a challenge for some people [to overcome].” 
–Law Enforcement Officer 
 
Challenges 
Reframing the Dialogue Around Effectiveness 
Taking into account the claims and concerns above, one of the main challenges discussed 
by the stakeholders regarding the potential implementation of SIFs was the need to reframe the 
public dialogue around the effectiveness of this intervention. Several stakeholders mentioned the 
need to educate the public on the benefits that this intervention has for a community rather than 
to let people maintain a negative image on IDUs and drug use in general. As explained, many 
people immediately assume that this intervention encourages and enables drug use, which is a 
challenge to the overall feasibility of this intervention. 
“Obviously when I say safe injection facilities, it sounds like I’m enabling people to get 
high, but if you frame it and teach people exactly what is happening inside a facility like 
this, I think you’d have a better shot at changing the public’s mind.” 
–Public Health Advocacy Organization Staff Member 
 
“I think just the pitch to the general public can be a bit of a challenge too. I think it would 
have to be framed carefully. Because some people are gonna see it as ‘so you just want a 
spot where people can come use drugs?’” 
–Law Enforcement Officer 
 
War on Drugs Rhetoric 
Another challenge that was widely discussed, especially by law enforcement officers, 
was the “war on drugs” attitude that has been the primary driver of drug policy in recent 
American history. Ultimately, injection drug use is illegal and the US justice system has spent 
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many years punishing those who use by imprisoning them, rather than connecting them to 
treatment and harm reduction resources. This attitude is still endorsed in North Carolina by many 
federal and state laws, and it is apparent in the actions of many law enforcement officials when 
working a drug case. Although a slight shift in this mindset has begun to spread across the US 
with the movement for legalization of marijuana, the war on drugs rhetoric persists as a major 
challenge to overcome in presenting IDUs as worthy of treatment and life-saving harm reduction 
interventions. 
“We’re not far removed from the war on drugs kind of mindset in law enforcement, and 
not just law enforcement, kind of in our communities. So, harm reduction philosophies 
are actually a pretty significant departure from the idea of the war on drugs, and it’s 
gonna take a little time to undo that sense in our community” 
–Law Enforcement Officer 
 
“We have to walk the walk and talk the talk. We have to do both, which means if your 
police chief is saying certain progressive things about harm reduction strategies, but your 
operational employees are actually acting like it’s still the war on drugs then you’re not 
gonna be successful. So, you need to have policies in place, training in place to police to 
understand why these strategies are important.” 
–Law Enforcement Officer 
 
“Well, we’ve done everything wrong, and therefore we have everything that we thought. 
We’ve criminalized drugs, we’ve locked people up instead of giving them help. The 
criminal justice system is the largest treatment provider which is the worst thing that you 
could do. We have historically criminalized harm reduction, we’ve historically 
criminalized harm reductionists. We’ve criminalized people who do drugs, we’ve 
criminalized people who treat them. We’ve prevented people from gaining treatment due 
to their criminal record.” 
–Public Health Advocacy Organization Staff Member 
 
Legal Framework 
In relation to the war on drugs rhetoric, another significant challenge that occludes the 
implementation of SIFs is the lack of a current legal framework. SIFs are not an intervention that 
can currently exist under federal laws or North Carolina state laws and unless these are altered to 
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prosecution. While this challenge has been present with other harm reduction interventions such 
as syringe exchange, as well as the legalization of marijuana, the degree to which SIFs defy the 
current laws that are in place is more extreme and unpredictable. Additionally, stakeholders 
expressed interest in observing the implementation and operation of SIFs in a legally sanctioned 
context within the United States before forming a final opinion on the logistics of 
implementation in North Carolina. Ultimately, if SIFs are ever going to be widespread across 
North Carolina, there will need to be major alterations to both federal and state drug policy that 
allow for it, and close examination on previously existing frameworks is necessary to ensure 
stakeholder buy-in on new legislation. 
“I would say the greatest legal barrier is that it’s federally illegal to use drugs or to have a 
place for people to be using drugs. I think that’s a major barrier.”  
–Public Health Advocacy Organization Staff Member 
 
“The law is symbiotic with social norms—we create them, we can reinforce them, and 
American drug law kind of says ‘well, it’s okay to use some drugs, but it’s not okay to 
use others.’ And of course, the drugs that are largely used in supervised consumption 
spaces are in the not okay category. So, in general, most people want to obey those laws 
most of the time, and they take their cues from the law, and if the law says these are 
illegal then a lot of people who haven’t looked into the matter too closely, you know, 
[their] standard first pass rubric is ‘well if something’s illegal, then it’s probably bad.’ So, 
they think well this is probably a bad idea.” 
–Health Policy Lawyer 
 
“The federal law [that makes it illegal to maintain any place for the purpose of 
manufacturing, distributing, or using any controlled substance] is called the Crack House 
Act, [which] wasn’t designed to stop or limit public health interventions. And that’s the 
argument about why the federal law shouldn’t be enforced this way, and the same with 
the state laws. States cannot be forced to follow federal law, you know if the feds want to 
come in and shut down a SIF under federal law, they can do that. Of course, if the feds 
want to come in and shut down syringe exchange programs under federal law, they can 
do that too. They never have.” 
 –Health Policy Lawyer 
 
 “First somebody else needs to do it. I know like Philadelphia, San Francisco, Seattle, 
New York, are all looking at it [legislation that allows for SIFs]. I think a lot of it is that 
we are interested in how the feds respond to this.” 
–Public Health Advocacy Organization Staff Member 
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Funding for SIFs 
Stakeholders also identified funding as a challenge to overcome if SIFs are to be 
effectively implemented in North Carolina. While there is a lot of dialogue in the media about 
the opioid crisis, there is a severe lack of funding for the necessary interventions which is only 
exacerbated with politically contentious and legally questionable interventions such as SIFs. 
Especially in the early stages of implementation, it will be nearly impossible to fund these 
facilities with state or federal dollars, making its success dependent on private funding.  
“I think other barriers [to overcome if SIFs are to be implemented in North Carolina] are 
public criticism [and] cost barriers—[there’s] not a lot of funding for it.” 
–EMS Provider 
 
“I think [SIFs are] a good model, I just think the challenge is always, resources, funding, 
you know that’s the big thing for long term therapy for a lot of these folks that are 
addicted, because as I understand it, it’s a hell of a challenge to get off this stuff.” 
–Law Enforcement Officer 
 
“The other thing is that we still don’t have funding for syringe exchange, [so] who’s 
gonna fund SIFs? They’re not gonna want to put any state dollars to this. Maybe RTI or 
somebody else could help us get funding for it. I think UNC, Duke, NC State, RTI, 
FHI360 are all viable funding sources. RTI has already invested in safe injection facilities 
in the United States underground for research. So, I think that there’s definitely interest in 
it, and you know having a base in the research triangle I think there’s a lot of interest in 
there.” 
–Public Health Advocacy Organization Staff Member 
 
Racial Implications 
The racial undertone of the opioid crisis is another nuanced challenge that stakeholders 
discussed in their interviews. This epidemic, as well as the response of the media and the public 
to this epidemic, are not independent of racial factors that dictate social patterns across the 
United States. While this challenge is not directly apparent to many who are directly impacted by 
the opioid crisis, there are factors of race that put people at greater risk of overdose or death from 
opioid use, and this has guided the public health response to this issue in comparison to 
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responses to previous drug crises. In order to successfully implement SIFs and provide equitable 
care across racial and socioeconomic divides, it is critical to consider the impact of America’s 
racist drug history and how this history has created the current disparities that exist. 
What’s different [about the opioid crisis now]? I mean a few things are different. One, 
there’s a lot more people dying. Two, they’re differently hued and they’re taking 
different drugs then people were taking in the ‘90s. They’re not gay. So, it’s a more 
socially acceptable epidemic now, which certainly has something to do with [the public 
dialogue and current public health response]. 
–Health Policy Lawyer 
 
“There’s a strong correlation with race and religion that are really risk factors for 
overdose, and I’m keenly aware of that.” 
–Public Health Advocacy Organization Staff Member 
 
 
Summary of Thematic Analysis 
 In consideration of all of the claims, concerns, and challenges revealed above, each of 
these themes were evaluated by stakeholder group for levels of awareness, concern, and priority, 
respectively. This was measured on a scale of high, medium, or low with regard to two factors: 
the prevalence in which the theme arose in interviews and a subjective measurement of apparent 
significance within each group. The summary of this assessment is presented in Tables 1-3 on 
page 27 below. Ultimately, while each of the themes outlined previously was identified across 
several stakeholder groups, a handful of the topics were determined to hold a high level of 
interest. The claim of highest awareness level was identified as the effectiveness of SIFs in 
relation to promoting health and safety of IDUs. In terms of concerns, the worries of SIFs stifling 
efforts at prevention, as well as efforts for treatment, were of the most concern across the 
stakeholder groups, but each of the other concerns was of high interest to specific stakeholders. 
The two primary challenges identified were the reframing of dialogue to focus on effectiveness 
and developing the legal framework to effectively establish and operate SIFs. 
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Table 1: Degree to which each stakeholder group states these claims 
 
Claims 
Effectiveness of 
Promoting Health 
and Safety for IDUs 
Effectiveness of 
Improving Public 
Safety 
Common Sense 
Policy 
Demonstrate 
Compassion 
and Humanity 
Public Health 
Advocacy and 
Operations 
High High High High 
Health Policy 
Law High Medium High High 
Local Law 
Enforcement Medium High Medium Medium 
Emergency 
Medical Services High Low Medium Medium 
 
Table 2: Degree to which each stakeholder group states these concerns 
 
Concerns 
Stifling 
Treatment 
Stifling 
Prevention 
Relation to 
Other Drug 
Use 
Privacy 
for IDUs 
NIMBY Enabling 
of Drug 
Use 
Public Health 
Advocacy and 
Operations 
Medium High High High Low Low 
Health Policy 
Law High High High Low High Low 
Local Law 
Enforcement Medium Medium Low High High High 
Emergency 
Medical Services Medium Medium Low Low Low High 
 
Table 3: Degree to which each stakeholder group states these challenges 
 
Challenges 
Reframing 
Dialogue  
War on Drugs 
Rhetoric 
Legal 
Framework 
Funding for 
SIFs 
Racial 
Implications 
Public Health 
Advocacy and 
Operations 
High Medium High High High 
Health Policy Law Medium Medium High Low High 
Local Law 
Enforcement High High High Medium Medium 
Emergency 
Medical Services High Low Medium Medium Medium 
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Discussion  
 
This qualitative study among key stakeholders with interests in the North Carolina opioid 
epidemic primarily examined the acceptance and potential feasibility of SIFs across the state. 
While the methods used were not designed to assess the overall frequency of opinions and their 
distribution in the general public, many themes were recurrently discussed amongst stakeholder 
groups. Each of these themes, representing different claims, concerns, and challenges of 
implementing SIFs, characterized the dialogue surrounding this intervention from the perspective 
of both public health experts and those who interact directly with the crisis. The experiences of 
these stakeholders suggest that there is much to consider before SIFs can be effectively 
implemented in North Carolina in the current social and political context of the state. 
Overall, there is lot of optimism amongst experts in the public health field, as well as law 
enforcement officers and EMS providers, in regards to favorable factors for implementing SIFs 
in North Carolina—effectiveness of promoting health and safety for IDUs, effectiveness of 
improving public safety, perception of SIFs as a common-sense policy, and the idea that SIFs 
demonstrate compassion for IDUs as people. These claims are accompanied by equally valid 
concerns—fear of SIFs stifling treatment or prevention efforts, external effects on non-opioid 
drug use and policy, privacy for IDUs, the NIMBY aversion, and the stigma of enabling drug 
use. Each of these factors are important to consider in overcoming the challenges that 
stakeholders identified—reframing the dialogue to focus on effectiveness, combating the war on 
drugs rhetoric, developing a comprehensive legal framework, procuring adequate funding and 
resources, and remaining sensitive to the racial implications of the crisis. 
There are several potential reasons that these themes emerged in this study. Countless 
factors contribute to individual perspectives on drugs and drug addiction, and each of these 
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perspectives evolves into a unique approach to managing drug use in society. Harm reduction is 
a specific category of intervention that does not neatly conform to the current set of US drug 
legislation, and SIFs are an extreme representation of this philosophy. Both people and 
institutions are often resistant to change, and SIFs represent a disruption to the status quo in 
American societal norms. Ultimately, the implementation of SIFs are a large step to take and 
stakeholders are hesitant to ensure that the step is being taken in the right direction. 
Although this study intended to examine stakeholder interests on multiple levels within 
the opioid crisis, limitations of time and resources made it difficult to assess such a complex 
issue. The participants’ responses were also limited by their own individual experience and 
knowledge concerning safe injection facilities, which are not necessarily representative of North 
Carolina as a whole. Finally, the study was limited to interviewing those who consented, and 
guided by snowball sampling which likely excluded people with negative attitudes towards harm 
reduction and safe injection facilities. Despite these limitations, the identified themes reached 
saturation as demonstrated by their recurrence across stakeholder groups, providing confidence 
that these results are meaningful and useful for guiding further research. 
To fully measure attitudes towards SIFs in North Carolina, next steps include assessing 
opinions and interests of IDUs in regard to regularly using SIFs, promoting unbiased educational 
campaigns that inform the general public on the benefits and concerns of SIFs, and researching 
effective legal frameworks that align with the socio-political context of North Carolina. 
 
Conclusion  
 
The prospect of implementing SIFs in North Carolina is a complex issue that involves 
stakeholders on several levels, and it should only be pursued with community support and full 
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understanding of the intervention. While most stakeholders have the same goals of decreasing 
morbidity and mortality from opioids, and increasing public safety, they seem to disagree on the 
necessity of certain interventions to achieve these goals. My findings suggest that several key 
stakeholders in North Carolina are aware of the possible benefits of SIFs and receptive to their 
possible implementation, but simultaneously hesitant to endorse such an intervention without 
further precedent in a local American context. Although more research needs to be conducted on 
IDU receptiveness to SIFs, by addressing the challenges presented and gathering more relevant 
evidence that this intervention satisfies a legitimate need, SIFs could be feasible within the 
context of North Carolina in the near future. 
  
 31 
References  
 
Ahrnsbrak, R., Bose, J., Hedden, S.L., Lipari, R.N. and Park-Lee, E. (2017). Key Substance Use 
and  Mental Health Indicators in the United States:  Results from the 2016 National 
Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics 
and Quality, Substance Abuse and Mental Health Services Administration.: Substance 
Abuse and Mental Health Services Administration. 
 
Birnbaum, HG, White, AG, Schiller, M, Waldman, T, Cleveland, JM, Roland, CL. (2011). 
Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United 
States. Pain Medicine, 12(4);657-667 
 
Brugha, R. and Varvasovszky, Z. (2000). Stakeholder analysis: a review. Health Policy and 
Planning 15(3), pp. 239–246. 
 
Bryson, J.M. (2004). What to do when Stakeholders matter. Public Management Review 6(1), 
pp. 21–53. 
 
Burris, S., & Lazzarini, Z. (2006). Rapid Policy Assessment and Response. Retrieved December 
06, 2017, from http://www.temple.edu/lawschool/phrhcs/rpar/index.html 
 
CDC WISQARS for opioid-related drug deaths (unintentional), Cost of Injury Reports, National 
Center for Injury Prevention and Control, CDC. Base year (2010) costs indexed to state 
2015 prices for poisoning deaths. 
 
Elliott, R., Malkin, I., & Gold, J. (2002). Establishing safe injection facilities in Canada: Legal 
and ethical issues. Montréal: Canadian HIV/AIDS Legal Network. 
 
Fairbairn, N., Small, W., Shannon, K., Wood, E. and Kerr, T. (2008). Seeking refuge from 
violence in street-based drug scenes: women’s experiences in North America’s first 
supervised injection facility. Social Science & Medicine 67(5), pp. 817–823. 
 
Florence, C.S., Zhou, C., Luo, F. and Xu, L. (2016). The economic burden of prescription opioid 
overdose, abuse, and dependence in the united states, 2013. Medical Care 54(10), pp. 
901–906. 
 
Guba, E. G., & Lincoln, Y. S. (1989). Fourth generation evaluation. Newbury Park, CA: Sage 
Publications. 
 
Havnes, I. (2015). Violence and diversion of prescribed opioids among individuals in opioid 
maintenance treatment. Institutt for Klinisk Medisin. 
 
Hawk, K. F., Vaca, F. E., & D’Onofrio, G. (2015). Reducing Fatal Opioid Overdose: Prevention, 
Treatment and Harm Reduction Strategies . The Yale Journal of Biology and Medicine, 
88(3), 235–245. 
 32 
 
Hedrich D. (2004). European report on drug consumption rooms. Lisbon: European Monitoring 
Centre for Drugs and Drug Addiction.  
 
Kerr T, Stoltz J, Tyndall M, et al. (2006). Impact of a medically supervised safer injection 
facility on community drug use patterns: a before and after study. BMJ 332: 220-222. 
 
Kerr T, Tyndall M, Li K, Montaner J, Wood E. (2005). Safer injection facility use and syringe 
sharing in injection drug users. Lancet 366:316-318.  
 
Kerr, T., Tyndall, M.W., Zhang, R., Lai, C., Montaner, J.S.G. and Wood, E. (2007). 
Circumstances of first injection among illicit drug users accessing a medically supervised 
safer injection facility. American Journal of Public Health 97(7), pp. 1228–1230. 
 
Kitsenko, G.; Shakhov, A.; Lazzarini, Z.; Case, P.; Chintalova-Dallas, R.; Burris, S. Harm 
reduction training in law schools in Ukraine. Proceedings of the 19th international harm 
reduction conference (IHRC); 2008. 
 
Knopf, T. (2017). Four North Carolina Cities Make Top 25 List for Opioid Abuse. Retrieved 
March 1, 2018, from https://www.northcarolinahealthnews.org/2017/07/27/four-north-
carolina-cities-make-top-25-list-opioid-abuse/ 
 
Kolodny, A., Courtwright, D.T., Hwang, C.S., Kreiner, P., Eadie, J.L., Clark, T.W. and 
Alexander, G.C. (2015). The prescription opioid and heroin crisis: a public health 
approach to an epidemic of addiction. Annual Review of Public Health 36(1), pp. 559–
574. 
 
Kozachenko, N.; Darbekova, G.; Mingazova, I.; Burris, S.; Case, P.; Chintalova-Dallas, R., et al. 
Evaluation of drug policy and HIV/AIDS prevention programs in Kazakhstan (Temirtau 
and Shymkent): Summary of RPA results. Proceeding of the 19th international harm 
reduction conference (IHRC); 2008. 
 
Lazzarini, Z.; Case, P.; Burris, S.; Chintalova-Dallas, R. Three easy policy changes to improve 
the risk environment for IDUs in Eastern Europe and the former Soviet Union Abstract 
#970 . Proceedings of the 18th International Harm Reduction Conference (oral 
presentation); 2007. 
 
Lopez, G. (2017, June 28). America leads the world in drug overdose deaths - by a lot. Retrieved 
December 06, 2017, from https://www.vox.com/policy-and-
politics/2017/6/28/15881246/drug-overdose-deaths-world 
 
Marlatt, G. A., Larimer, M. E., & Witkiewitz, K. (Eds.). (2011). Harm Reduction, Second 
Edition: Pragmatic Strategies for Managing High-Risk Behaviors (Second ed.). New 
York, NY: The Guilford Press. 
 
 33 
Metz V, Sullivan M, Jones JD. (2018). Sexual and drug use risk behaviors and HIV- and 
Hepatitis-C transmission knowledge among non-treatment-seeking individuals with 
opioid use disorders in NYC. Drug Alcohol Depend, 171:e143-e144. 
doi:10.1016/j.drugalcdep.2016.08.397. 
 
N.C. State Center for Health Statistics, Vital Statistics-Deaths, (1999-2016); N.C. State Center 
for Health Statistics, Vital Statistics- Hospitalizations, 2016; NC DETECT, 
2014.NSDUH 2013-2016. CSRS 2014.  
 
Nodulman, J.A., Starling, R., Kong, A.S., Buller, D.B., Wheeler, C.M. and Woodall, W.G. 
(2015). Investigating stakeholder attitudes and opinions on school-based human 
papillomavirus vaccination programs. The Journal of School Health 85(5), pp. 289–298. 
 
Paulozzi LJ. (2010). The epidemiology of drug overdoses in the United States. Presented at 
Promis. Leg. Responses to the Epidemic of Prescr. Drug Overdoses in the U.S., 
Maimonides Med. Cent. Dep. Psychiatry, Dec. 2, Grand Rounds, Brooklyn  
 
Petruney, T., Harlan, S.V., Lanham, M. and Robinson, E.T. (2010). Increasing support for 
contraception as HIV prevention: stakeholder mapping to identify influential individuals 
and their perceptions. Plos One 5(5), p. e10781. 
 
Philbin, M.M. and FuJie, Z. (2014). Exploring stakeholder perceptions of facilitators and barriers 
to using needle exchange programs in Yunnan Province, China. Plos One 9(2), p. e86873. 
 
Pishchulin, V.I., Rogacheva, L.I., Fokina, L.V., Fadeeva, O.M., Novikov, R.A. and Kolupaev, 
R.V. (2014). Drug addiction prevention: experience of high education institute. Life 
Science Journal 11(12), pp. 566–569. 
 
Searle, R. (2017). Opioids and Driving. Rheumatology, 56(2) 
https://doi.org/10.1093/rheumatology/kex060.107 
 
Small, W., Kerr, T., Charette, J., Schechter, M.T. and Spittal, P.M. (2006). Impacts of intensified 
police activity on injection drug users: Evidence from an ethnographic investigation. 
International Journal of Drug Policy 17(2), pp. 85–95. 
 
Small, W., Rhodes, T., Wood, E. and Kerr, T. (2007). Public injection settings in Vancouver: 
physical environment, social context and risk. The International journal on drug policy 
18(1), pp. 27–36. 
 
Small, W., Wood, E., Lloyd-Smith, E., Tyndall, M. and Kerr, T. (2008). Accessing care for 
injection-related infections through a medically supervised injecting facility: a qualitative 
study. Drug and Alcohol Dependence 98(1–2), pp. 159–162. 
 
Sobeyko, J.; Duklas, T.; Parczewski, M.; Leszczyszyn-Pynka, M.; Bejnarowicz, P.; Lazzarini, Z., 
et al. After the rapid policy and response process: Drug policy change in Szczecin, 
 34 
Poland. Abstract #668. Proceedings of the 18th international harm reduction conference 
(poster presentation); 2007. 
 
Stoltz J, Wood E, Small W, et al. (2007). Changes in injecting practices associated with use of a 
medically supervised safer injection facility. J Public Health (Oxf) 29:35-39.  
 
Thein H-H, Kimber J, Maher L, MacDonald M, Kaldor JM. (2005). Public opinion towards 
supervised injecting centres and the Sydney Medically Supervised Injecting Centre. Int J 
Drug Policy 16:275-280.  
 
Vyshemirskaya, I.; Osipenko, V.; Burkhanova, O.; Lazzarini, Z.; Burris, S.; Chintalova-Dallas, 
R., et al. Initiating practical health interventions for IDUs in Kaliningrad, Russia: Results 
of a rapid policy assessment and response (RPAR). Proceedings of the 19th international 
harm reduction conference (IHRC); 2008. 
 
Wood E, Kerr T, Small W, et al. (2004). Changes in public order after the opening of a medically 
supervised safer injecting facility for illicit injection drug users. Can Med Assoc J 
171:731-734.  
 
Wood E, Tyndall M, Lai C, Montaner J, Kerr T. (2006). Impact of a medically supervised safer 
injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev 
Policy 1:1 – 4. 
 
Wood E, Tyndall MW, Zhang R, et al. (2006). Attendance at supervised injecting facilities and 
use of detoxification services. N Engl J Med 354:2512-2514. 
 
 
   
 35 
Appendix A 
 
Interview Guide 
1. What do you know about the opioid crisis in North Carolina? 
a. What causes it?  
b. Is it getting any better?  
c. What interventions have been effective at combating this? 
2. What information do you already know about SIFs and how does this impact your 
opinions? 
3. What opinions do you think others have about SIFs and harm reduction methods? 
4. What are possible legal and social obstacles to the implementation of SIFs in North 
Carolina? 
a. Do bigger obstacles exist on a local, state, or national level? 
5. Which harm reduction interventions do you see as feasible in North Carolina’s current 
political and social context? 
6. What do you see as the most effective way to promote health and safety among IDUs in 
North Carolina? 
7. As a community member and as a professional, what role do you see yourself playing in 
overcoming the opioid crisis? 
8. What further information would you like to know about to form an opinion on SIFs? 
a. If SIFs were to be implemented in North Carolina tomorrow, what would be your 
concerns, thoughts, and hesitations? 
